Prognostic factors for tumour response and survival after chemoembolization treatment

• Autores: María Muros Ortega, María Sacramento Díaz Carrasco, Antonio Capel Alemán, Miguel Angel Calleja Hernández, Fernando Martínez Martínez
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 17, Nº. 6, 2015, pág. 2
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Background: Doxorubicin-eluting bead transarterial chemoembolization is a palliative treatment option in unresectable hepatocellular carcinoma and a bridge to liver transplantation.

    Purpose: Identified prognostic factors that improve overall and progression-free survival and help to achieve better tumour response in patients after chemoembolization.

    Method: Tumour response was classified as complete or other, and analysed by age, sex, number of lesions, tumour size, albumin, bilirubin and alpha-fetoprotein level and procedure indication. Overall and progression-free survival were analysed by sex, Child-Pugh class, Okuda score, ECOG PS, tumour response, albumin, bilirubin and alpha-fetoprotein level and indication. Significant differences found were considered possible prognostic factors.

    Results: After tumour response analysis significant differences were observed in age, number of lesions and albumin level. In survival analysis were found differences in Child-Pugh class, Okuda score, ECOG PS, albumin, bilirubin and alpha-fetoprotein level and tumour response.

    Conclusions: Prognostic factors associated with better tumour response were being young, having fewer lesions and albumin greater than 4 g/dL. Prognostic factors associated with higher overall and progression-free survival were Child-Pugh A,Okuda I and ECOG 0, albumin greater than 3 g/dL, bilirubin lower than 2 mg/dL and achieving complete tumour response. Alpha-fetoprotein lower than 400 ng/mL were associated with better overall survival